

DAFTAR PUSTAKA

- Adams J, Cardes PJ, Downey S, Forbes MA, et al. VEGF in Breast Cancer Comparison of Plasma, Serum and Tissue VEGF and Microvessel Density and Effects of Tamoxifen. *Cancer Research*. 2000; 60; p: 2898-905.
- Aktas A, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel, Tewes M and on behalf of the DETECT Study Group. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. *BMC Cancer*; 2016: 16:522.
- Ali ME, Sheta M, El Mohsen MA. Elevated Serum and Tissue VEGF Associated with Poor Outcome in Breast Cancer Patients. *Alexandria J Med*. 2011; 47; p: 217-24.
- Almumen. M. 2015. Immunohistochemical Expression of VEGF in Relation to Other Pathological Parameters of Breast Carcinoma. *Journal of Cancer Therapy*, 2015, 6, 811-820.
- American Cancer Society. *Cancer facts and Figure*. Atlanta American Cancer Society. 1994.
- American Joint Committee on Cancer. Breast. In : Greene FL, Compton CC, Fritz AG, Shah JP, Winchester JP, editors. *AJCC Cancer Staging Atlas*. Springer, 2006; p: 217-33.
- Andrea, O., & Sankar, G. 2009. The NF- κ B family of transcription factors and its regulation. *Cold Spring Harbor Laboratory Press*, 1, 1-14.
- Ariga, A., Namekawa, J., Matsumoto, N., Inoue, J. & Umezawa, K. 2002. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. *J Biol, Chem*. 277, 24625-30.
- Ayoub NM, Jaradat SK, Al-Shami KM and Alkhalifa AE. Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. *Frontiers in Pharmacology*. 2022: 13.

- Bardia, et al. Recreational Physical Activity and Risk of Post Menopause Breast Cancer Based on Hormon Receptor Status. *Arch Intern Med.* 2006. Dec.11-25. 166(22); p:2478-83.
- Barisic, S., Strozky, E., Peters, N. & Kulms, D. 2008. Identification of PP2A as a crucial regulator of the NF-kappaB into a pro-apoptotic factor. *Cell Death Differ.* (15): (11). 1681-90.
- Barr, M. P., Gray, S. G., Haffmann, A. C., Hilger, R. A., Thomale, J. & Flaherty, J. 2013. Generation and characterisation of cisplatin resistant non small cell lung cancer cell lines displaying a stem like signature. *PLoS One* 8:e 54193.
- Boedina S. Angiogenesis dan Metastasis. In : Ilmu Dasar Onkologi, Fakultas Kedokteran Universitas Indonesia, 2011; p: 220-53.
- Bonizzi, G. & Karin, M. 2004. The two NF-kB activation pathway and their role in innate and adaptive immunity. *Trends Immunol*, 25, 280-8.
- Bottero, V., Busuttil, V., Loubat, A., Magne, N., Fischel, J. L., Milano, G. & Peyron, J. F. 2001. Activation of nuclear factor κ B through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. *Cancer Research*, 61, 7785-91.
- Brown LF, Berse B, Jackman RW. Expression of Vascular Permeability Factor (VEGF) and Its Receptors in Breast Cancer. *Hum Pathol.* 1995; 26; p: 86-91.
- Bucur, O., Ray, S., Bucur. M. C. & Almasan, A. 2006. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. *Frontiers in Bioscience*, 11, 1549-68.
- Byrne GJ, Mc Dowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. Serum Vascular Endothelial Growth Factor in Breast Cancer. *Anticancer Research.* 2007; 27; p: 3481-88.
- Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J. & Gradishar, W. J. 2009. Breast cancer. *Journal of the National Comprehensive Cancer Network*, 7, 122-92.

- Chen. L. F. & Greene. W. C. 2004. Targeting of RelA by multiple protein kinases induced by distinct stimuli. *Nature Reviews Molecular Cell Biology*, 5, 392-401.
- Cimpean AM, Raica M, Suciuc C, Tatucu D, Sarb S, Muresan AM. Vascular Endothelial Growth Factor A (VEGF A) as Individual Prognostic Factor in Invasive Breast Carcinoma. *Rom J Morphol Embryo*. 2008; 49(3); p:303-8.
- Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K. And Baldwin, A. S. 2000. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B alternative pathway (p100/p52) and for Bcl-3. *Oncogen*. 19: (9),1123-31.
- Connolly, R. M. & Stearns, V. 2013. Current approaches for neoadjuvant chemotherapy in breast cancer. *European journal of pharmacology*, 717, 58-66.
- Crowley, J. E., Treml, L. S., Stadanlick, J. E., Carpenter, E. & Cancro, M. P. 2005. Homeostatic niche specification among naive and activated B cells: a growing role for the BlyS family of receptors and ligands. *Semin, Immunol*. 17, 192-9.
- De Benedetti, A., & Graff, J. R. 2004. eIF-4E expression and its role in malignancies and metastases. *Oncogene* 23, 3189-99.
- Denkert, C., Sinn, B. V., Issa, Y., Muller, B. M., Maisch, A., Untch, M., Von Minckwitz, G. & Loibl, S. 2011. Prediction of response to neoadjuvant chemotherapy: new biomarker approaches and concepts. *Breast Care*, 6, 265-72.
- Devesa J, and Caicedo D. The Role of Growth Hormone on Ovarian Functioning and Ovarian Angiogenesis. *Frontiers in Endocrinology*. 2019, 10(450).
- Dowlatshahi Kambiz. Abnormal mammography; in *Surgical Oncology an Algorithmic Approach*, New York: Springer-Verlag inc; 2003; p: 188-95.
- Duffy, M. J. 2013. Tumor markers in clinical practice: a review focusing on common solid cancers. *Med Princ Pract*, 22, 4-11.
- Ebeid SA, Al-Moneim NA, Soliman KE, Zaher ER, Soliman YA. Evaluation of The Role of Serum Tissue Inhibitor of Matrix Metalloproteinase 1 (TIMP-1) in

- Vascular Endothelial Growth Factor (VEGF) Induction and Their Role in Prognosis of Breast Cancer Patients. *J Med Reseach Inst.* 2009; 30(1); p: 29-39.
- Eisenhauer, E., Therasse, P., Bogaerts, J., Schwartz, L., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S. & Money, M. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1,1). *European journal of cancer*, 45, 228-47.
- El Saghir. Breast Cancer In Arab Countries. *PAJO.* 2009. Apr.2(2); p:14-5.
- Ellis IO. Invasif Breast Carsinoma. Tumours of Breast. Pathology and Genetics of Tumours of The Breast and Female Genital Organs. WHO Classification of Tumours. Chapter 1. Tavassoli. 2003; p: 10-30.
- Elmore, S. 2007. Apoptosis: A review of programmed cell death. *Toxicol Pathol*, 35, 495-516.
- Engstrom, M., Opdhal, S., Hagen, A., Romundstad, P., Akslen, L., Haugen, O., Vatten, L. & Bofin, A. 2013. Molecular subtypes, histopatological grade and survival in a historic cohort of breast cancer patients. *Breast cancer research and treatment*, 140, 463-73.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer.* 2015; 136: E359-E386.
- Ferrara N. VEGF as a Therapeutic Target in Cancer. *Oncology.* 2005; 69(3); p: 11-6.
- Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Crus, A., Fisher, E.R., Wickerham, D. L. & Wolkmark, N. 1997. Effect of preoperative chemotherapy on local regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. *Journal of Clinical Oncology*, 15, 2483-93.
- Folkman J. Tumor angiogenesis. In : Mendelsohn J, Howley PM, Israel M, Liotta LA, editors. *The Molecular Basis of Cancer.* Philladelphia, W.B Saunders Co. 1995; p: 206-25.

- Fountzilias, G., Dafni, U., Bobos, M., Kotoula, V., Batistatou, A., Xanthakis, I., Papadimitriou, C., Kostopoulos, I., Koletsa, T. & Tsolaki, E. 2013. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. *BMC cancer*, 13, 123-63.
- Freeman MR, Schneck FX, Gagnon MI, Corles C, Sokes S, Niknejad K. Peripheral Blood T Lymphocytes and Lymphocytes Infiltrating Human Cancers Express VEGF. A Potential Role for T cell in Angiogenesis. *CancerRes*, 1995; 55: p: 4140-45.
- Fučkar D, Dekanić A. Štifter S, Mustać E, Krstulja M, Dobrila F, dan Jonjić N. VEGF Expression is Associated with Negative Estrogen Receptor Status in Patients with Breast Cancer. *International Journal of Surgical Pathology*, 2006; 14(1):49-55.
- Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in Primary Breast Cancer. *Breast Cancer Research and Treatment*. Vol 22(3), 1992; p: 207-19.
- Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M. Prognostic Significance of Vascular Endothelial Growth Factor Protein in Node-negative Breast Carcinoma. *J. Natl, Cancer Inst*. 1997; 89; p: 139-47.
- Gisterek I, Szewczyk K, Matkowsky R, Sedlaczek P, et all. Serum VEGF-A₁₆₅ Level in Patient with Various Histological types of Breast Cancer and Benign Tumor. *J.Clin Oncol*. 2008; 26; p: 221-30.
- Gong, C., Yao, H., Liu, Q., Chen, J., Shi, J., Su, F. & Song, E. 2010. Markers of tumor-initiating cells predict chemoresistance in breast cancer. *Plos one*, 5, e15630.
- Goussia A, Simou N, Zagouri F, Manousou K, Lazaridis G, Gogas H, et al. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.

- PLoS ONE, 2018; 13(7): e0200302. Mamoor, S. High VEGF-A expression distinguishes basal-like human breast cancer. OSF.IO; 2021.
- Grandage, V. L., Gale, R. E., Linch, C. & Khwaja, A. 2005. P13-kinase/ Akt is constitutively active in primary acute myeloid leukemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. *Leukimia* 19, 586-94.
- Heer K, Kumar H, Read JR. Serum Vascular Endothelial Growth Factor in Breast Cancer : Its Relation with Cancer Type and Estrogen Receptor Status. *Clin Cancer Res.* 2001; 7; p: 3491-4.
- Hicklin DJ, Ellis LM. Interactions of VEGF ligands and VEGF Receptors. *J Clin Oncol.* 2005; 23; p: 1011-27.
- Hinz, M. & Scheidereit, C. 2014. The IkappaB kinase complex in NF-kappaB regulation and beyond. *EMBO Rep.* 15: (1). 46-81.
- Hoar FJ, Lip FYH, Belgore F, Stonelake PS. Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFlt-1) in human breast cancer. *The International Journal of Biological Markers*, 2004; 19(3): 229-235.
- Hodorowicz-Zaniewska D, Kibil W, Małek A, Szpor J, Kulig J, Sztefko K. Evaluation of serum concentrations of vascular Endothelial growth factor (vegf) in breast cancer Patients. *Pol j pathol* 2012; 63: 255-260.
- Indra, Sampepajung D, Haryasena and Faruk M. Correlation between vascular endothelial growth factor-a serum with clinical stage, histopathologic grading and estrogen receptor status breast cancer patient in makassar. *International Journal of Surgery and Medicine*, 2021: 7(1):43-47
- Inwald EC, Klinkhammer-Schalke M, Hofstaädter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O, Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. *Breast Cancer Res Treat*, 2013: 139:539–552.
- Ivshina AV, George J, Senko O et all. Genetic Reclassification of Histologic Grade Delineates new Clinical Subtypes of Breast Cancer. *Molecular Biology. Pathobiology and Genetics.* Departement of Pathology Sweden. 2006.

- Jin YH, Hua QF, Zheng JJ, Ma XH, Chen TX, Zhang S, Dai BCQ, Zhang XH. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer. *Cell Physiol Biochem* 2018; 49:271-281.
- Karim, M. & Lin, A. 2002. NF-kappaB at the crossroads of life and death. *Nat Immunol*,3, 221-27.
- Kim, R., Emi, M. & Tanabe, K. 2006. The role of apoptosis in cancer cell survival and therapeutic outcome. *Cancer Biol Ther*, 5(11), 1429-42.
- Konukoglu D, Turhan D, Sultan M, Varol C, Turna, Hande. Relation of Serum VEGF as An Angiogenesis Biomarker with Nitrit Oxide and Urokinase-Type Plasminogen Activator in Breast Cancer Patients. *Indian J Med Res*. 2007, Sept (12); p: 17-21.
- Kurosaka, K., Takahashi, M., Watanabe, N., & Kobayashi, Y. 2003. Silent clean up of very early apoptotic cells by macrophages. *J*, 171, 4672-9.
- La'hteenvuo J, Rosenzweig A. Effects of Aging on Angiogenesis. *Circulation Research*, 2012.
- Lee, A., Lim, W., Moon, B. I., Paik, N. S., Koh, S. H. & Song, J. Y. 2011. Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline and taxane based chemotherapy. *Journal of breast cancer*, 14, 283-8.
- Lester SC. The Breast in Text book of Robbin's Pathologic Basic of Disease; Chapter 23. 8th Ed. Phil. W.B Saunders Co. 2010; p: 1083-90.
- Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular Endothelial Growth Factor is of High Prognostic value in Node-negative Breast Carcinoma. *J. Clin. Oncol*. 1998; 16; p: 3121-8.
- Liu Y, Tamimi RM, Collins LC, Schnitt SJ. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. *Breast Cancer Res Treat*. 2011; 129(1): 175–184.

- Liu, Y., Du, F., Chen, W., Yao, M., Lv, K. & Fu, P. 2013. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. *Experimental cell research*, 319, 3140-9.
- Longley, D. & Johnston, P. 2005. Molecular mechanisms of drug resistance. *The journal of pathology*, 205, 275-92.
- Maiello MR, De Luca A, Gallo M, D'Alessio G, Normanno N. Signal Transduction Inhibitors in The Treatment of Breast Cancer. In : Giordano A, Normanno N. Editors. Breast cancer in The Post Genomic Era. 2009; p: 177-202.
- Martin GS. Normal cells and Cancer cells in : Bishop JM, Weinstein RA, editors. Molecular Oncology. New York: Scientific American. 1996; p: 13-40.
- Masood S. Prediction of Recurrence for Advance Breast Cancer. Traditional and Contemporary Pathologic and Molecular Markers. *Surg Oncol Clin N Am*, 1995; Oct.4(4); p: 601-32.
- McGuire A, Brown JAL, Malone C, McLaughlin R and Kerin MJ. Effects of Age on the Detection and Management of Breast Cancer. *Cancers* 2015; 7, 908-929; doi:10.3390/cancers7020815.
- Morales N, Morimoto S, Vilchis F, Taniyama N, Bautista VJ, Robles C and Enrique bargalló2. Molecular expression of vascular endothelial growth factor, prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast. *Oncology Letters*, 2016; 12: 2720-2727.
- National Comprehensive Cancer Network. Breast Cancer. 2008. Online at: www.nccn.org.
- Ntirenganya F, Twagirumukiza JD, Bucyibaruta, Rugwizangoga, and Rulisa S. remenopausal Breast Cancer Risk Factors and Associations with Molecular Subtypes: A Case-Control Study. *International Journal of Breast Cancer*, 2021.
- O'Reilly MS, Boehm T, Shing Y, et al. Endostatin : An Endogenous Inhibitor of Angiogenesis and Tumor Growth. *Cell J*, Jan. 1997, 88(2); p: 277-85.

- Okano H et al. Effects of A Moderate-intensity Static magnetic Field on VEGF-A Stimulated Endothelial Capillary Tube Formation in Vitro. *Bioelectromagnetics*. 2006; 27(8); p: 628-40.
- Pacifico, F. & Leonardi, A. 2006. NF- κ B in solid tumors. *Biochemical pharmacology*, 72, 1142-52.
- Page, R. & Takimoto, C. 2001. Principles of chemotherapy. *Cancer management: a multidisciplinary approach, 5th ed. Melville, NY: PRR, Inc.* 20-31
- Pavlou. M. P., Diamandis E. P. & Blasutig, I. M. 2013. The long journey of cancer biomarkers from the bench to the clinic. *Clin Chem*. 59, 147-57.
- Perkins, N. D. 2007. Integrating cell-signalling pathways with NF- κ B and IKK function. *Nature Publishing Group*, 8, 49-62.
- Press, M. F., Sauter, G., Buyse, M., Bernstein, L., Guzman, R., Santiago, A., Villalobos, I. E., Eiermann, W., Pienkowski, T. & Martin, M. 2011. Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. *Journal of Clinical Oncology*, 29, 859-67.
- Prosnitz LR, Iglehart JD, Winer EP. Breast Cancer. In : Rubin P, editors. *Clinical Oncology, A Multidisciplinary Approach for Physicians and Students*, 8th ed. WB Saunders Co. 2001; p: 267-96.
- Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoen, J. L., Vogel, V. G. & Dakhil, S. R. 2008. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. *Journal of Clinical Oncology*, 26, 778-85.
- Razani, B., Zarnegar, B., Ytterberg, A. J., Shiba, T., Loo, J. A. & Cheng, G. 2010. Negative feedback in noncanonical NF- κ B signaling modulates NIK stability through IKK α -mediated phosphorylation. *Sci Signal*. 3: (123). 41.
- Rhodes, A. & Yip, C. 2011. Comparison of breast cancer in Indonesia and Malaysia a clinico-pathological study between Dharmais Cancer Centre

- Jakarta and University Malaya Medical Centre, Kuala Lumpur. *Asian Pacific Journal of Cancer Prevention*, 12, 2943-46.
- Rosai J. The Breast in Text Book of Ackerman's Surgical Pathology. 9th Ed. ST. Louis: Mosby. 2004; p: 1763-876.
- Rosen P. Invasif Ductal Carcinoma Assesment of Prognosis, Morphologic Prognostic Markers and Tumor Growth Rate. In : Text book of Rosen's Breast Pathology, 3rd Ed. 2009; p: 369-79.
- Sahana KR, Akila P, Prashant V, Chandra BS, Suma MN. Quantitation of Vascular Endothelial Growth Factor and Interleukin-6 in Different Stages of Breast Cancer. *Reports of Biochemistry & Molecular Biology*, 2017; 6(1).
- Sainsburry, Anderson TJ, Morgan DAL. Breast Cancer. *BMJ*, 2000: 321; p: 745-51.
- Sampepajung D. Kanker Payudara di Indonesia, Masalah dan Penanggulangannya. Naskah Pidato pada Upacara Pengukuhan sebagai Guru Besar Bidang Ilmu Bedah onkologi Fakultas Kedokteran Universitas Hasanuddin, Makassar, 27 Desember 2010.
- Sampepajung D. Pendekatan Biologi Molekuler pada Penderita Kanker Payudara dan Keluarga Seketurunan dengan pelacakan Mutasi Gen BRCA-1 di Makassar. Disertasi Program Pasca Sarjana Universitas Hasanuddin, Makassar, 2003.
- Schnitt SJ. Traditional and Newer Pathologic Factors. *J Natl Cancer Inst Monogr*, 2001; 30; p: 22-6.
- Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, O'Brien KM, Adami HO, Baglietto L, Bernstein, Bertrand KA, et al. Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women. *Int. J. Cancer*, 2020; 147, 1306–1314.
- Shivakumar S, Prabhakar BT, Jayashcee K, Rajen MG, Salimath BP. Evaluation of Serum VEGF and Microvessel Density (MVD) as Prognostic Indicator in Carcinoma Breast. *J Cancer Res Clin Oncol*. 2009; 135: p: 627-36

- Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian, N. Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast. *Iranian Journal of Pathology*, 2015; 10(3): 221 – 226.
- Sidhu SS, Kossiakoff AA. Exploring and Designing Protein Function with Restricted Diversity. *Curr. Opin. Chem. Biol.* 2007; 11; p: 347-54.
- Solorzano CC, Ahearne PM, Leach SD. Invasif Breast Cancer. In : Berger DH, Feigh BW, Fuhrman, editors. *The MD Anderson Surgical Oncology Handbook*, 3th ed. Lippincott Williams and Wilkins. 2003; p: 14-28.
- Speth, P., Van Hoesel, O. & Haanen, C. 1988. Clinical pharmacokinetics of doxorubicin. *Clinical pharmacokinetics*, 15, 15-31.
- Sukardja IDG. Etiologi Kanker dalam Onkologi Klinik, Edisi 2, Airlangga University Press, Surabaya. 2000: p: 113-25.
- Surakasula A, Nagarjunapu GC, Raghavaiah. [A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management.](#) *Journal of Research in Pharmacy Practice*, 2014; 3(1)
- Tanaka, K., Babic, I., Nathanson, D., Akhavan, D., Guo, D. & Gini, B. 2011. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. *Cancer Discov.* 1, 524-38.
- Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, Inoue K. Classical and Novel Prognostic Marker for Breast Cancer and Their Clinical Significance. *ClinMed Insight Oncol.* 2010: 4; p: 15-34.
- Thomas, A., Bucholz., Amit, K & Grag. 2005. The nuclear transcription factor kB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. *American Association for Cancer Research.* 11, 8398-403.
- Tjindarbumi D, Ramli M. Clinicopathological Aspect of Breast Cancer. A Joint Study between Indonesia and Japan. *Med J of Indonesia.* 1995: 4(3):143-8
- Viennois, E., Chen, F. & Merlin, D. 2013. NFkB pathway in colitis-associated cancers. *Transl Gastrointest Cancer*, 2 (1), 21-9.

- Vincent T. De Vita, E. C. 2008. Principles Of Cancer Chemotherapy. *In: Edward Chu, V. T. D. V. (ed.). Physicians cancer chemotherapy drug manual 2008. Massachusetts: Jones and Bartlett. 34-42.*
- Vogl G, Bartel H, Dietze O, Hauser-Kronberger C. Her2 is Unlike to be Involved in Directly Regulating Angiogenesis in Human Breast Cancer. *Appl Immunohistochem Mol Morphol.* 2006; 14(2); p: 138-45
- Volkavic T, Dobrila F, Melato M, Sasso F, Rizadi C, Jonjic N. Correlation between VEGF, Angiogenesis, Tumor Associated Macrophages in Invasive Ductal Carcinoma Breast Cancer. *Virchows Arch.* 2002; 440; p:583-8.
- Weinberg, R. 2007. P53 and apoptosis: Master guardian and executioner. *In : The Biology of Cancer. New York, Garland Sc.* 101. 307-356.
- Westerblad, H., Clair, D. K. S., Reid, M. B., Gilliam, L. A., Ferreira, L. F., Bruton, J. D. & Moylan, J. S. 2011. Doxorubicin acts through tumor necrosis factor. *J Appl Physiol*, 110, 935-42.
- Willet WC, Rockhill B, Hankinson SE, Hunter DJ, Colditz GA. Epidemiology and Non Genetic Causes of Breast Cancer. *In : Harris JR, Lippman MC, Morrow M, Osborne CK, editors. Disease of The Breast. 2nded. Lippincott Williams and Wilkins, Philadelphia. 2000; p: 175-220.*
- Wilson, T., Longley, D. & Johnston, P. 2006. Chemoresistance in solid tumours. *Annals of oncology*, 17, 315-24.
- Wong, R. S. Y. 2011. Apoptosis and cancer: from pathogenesis to treatment. *J Exp & Clin Cancer Res* 2011, 30: 87. Diunduh dari <http://www.jeccr.com/content/30/1/87>.
- Yamamoto Y, Kondo S, Toi M, Matsumoto T, Suzuki H, et al. Concentrations of Vascular Endothelial Growth Factor in the Sera of Normal Control and Cancer Patients. *Clin Cancer Res.* 1996; 2; p: 821-6.
- Yancopoulos GD, et al. Vascular-specific Growth Factor and Blood vessel Formation. *Nature.* 2000; 407; p: 242-8.
- Yao, L., Liu, Y., Li, Z. Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T. & Lin, B. 2011. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. *Annals of Oncology*, 22, 1326-31.

- Zhao J, Yan F, Ju H, Tang J, Qin J. Correlation between Serum Vascular Endothelial Growth Factor and Endostatin Level in Patients with Breast Cancer. *J CanLet*. 2004, (204); p: 87-95
- Zhou, Y., Eppenbergs-Castori, S., Epenberg, U. & Benz, C. C. 2005. The NF κ B pathway and endocrine resistant Breast cancer. *Endocrine –Related Cancer*. 37-46.
- Zinzalla, V., Straca, D., Oppliger, W., & Hall, M. N., 2011. Activation of mTORC2 by association with the ribosome. *Cell*, 144, 757-68.